These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16181774)

  • 1. Diurnal variation in plasma homovanillic acid in patients with schizophrenia and healthy controls.
    Duncan E; Bollini AM; Sanfilipo M; Wieland S; Angrist B; Cooper TB; Rotrosen J
    Schizophr Res; 2006 Jan; 81(2-3):323-6. PubMed ID: 16181774
    [No Abstract]   [Full Text] [Related]  

  • 2. Persistence of cyclicity of the plasma dopamine metabolite, homovanillic acid, in neuroleptic treated schizophrenic patients.
    Davila R; Zumarraga M; Andia I; Friedhoff AJ
    Life Sci; 1989; 44(16):1117-21. PubMed ID: 2565009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
    Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
    Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.
    Koshikawa H; Suzuki E; Kanba S; Nibuya M; Ishizuki T; Kohno H; Kinoshita N; Shintani F; Yagi G; Nakaki T
    Yakubutsu Seishin Kodo; 1991 Feb; 11(1):79-81. PubMed ID: 1679276
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
    Chen TY; Lee CF; Lung FW; Lee TC; Lin WL; Hu WH; Yeh EK; Chang WH
    Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):584-8. PubMed ID: 2571672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenia and plasma homovanillic acid in response to mental stress: methodological considerations.
    Sumiyoshi T; Kurachi M; Itoh H
    Neuropsychopharmacology; 2000 Sep; 23(3):347-9. PubMed ID: 11032429
    [No Abstract]   [Full Text] [Related]  

  • 7. Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia.
    Doran AR; Labarca R; Wolkowitz OM; Roy A; Douillet P; Pickar D
    Arch Gen Psychiatry; 1990 Jun; 47(6):558-63. PubMed ID: 2350208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diurnal variation in plasma homovanillic acid: not a renal phenomenon.
    Stroe AE; Amin F; Hashmi A; Densmore D; Kahn T; Knott PJ
    Biol Psychiatry; 1997 Mar; 41(5):621-3. PubMed ID: 9046995
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma homovanillic acid and prognosis in schizophrenia.
    Baker NJ; Kirch DG; Waldo M; Bell J; Adler LE; Hattox S; Murphy R; Freedman R
    Biol Psychiatry; 1991 Jan; 29(2):192-6. PubMed ID: 1671646
    [No Abstract]   [Full Text] [Related]  

  • 10. Measurements of plasma homovanillic acid in schizophrenic patients.
    Davidson M; Kahn RS; Stern RG; Harvey PD; Keefe R; Knott P; Apter S; Webster L; Davis KL
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():521A-522A. PubMed ID: 1354058
    [No Abstract]   [Full Text] [Related]  

  • 11. Evidence for a daily rhythm of plasma HVA in normal controls but not in schizophrenic patients.
    Doran AR; Pickar D; Labarca R; Douillet P; Wolkowitz OM; Thomas JW; Roy A; Paul SM
    Psychopharmacol Bull; 1985; 21(3):694-7. PubMed ID: 4034886
    [No Abstract]   [Full Text] [Related]  

  • 12. Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients.
    Zumárraga M; Dávila R; González-Torres MA; Anguiano JB; Zabalo MJ; Basterreche N; Arrúe A; Zamalloa MI; Guimón J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):713-9. PubMed ID: 17291661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of plasma HVA and treatment response in a large series of patients with schizophrenia.
    Davila R
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():519A-520A. PubMed ID: 1354057
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia.
    Kelley ME; Yao JK; van Kammen DP
    Neuropsychopharmacology; 1999 Jun; 20(6):603-11. PubMed ID: 10327429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
    Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
    Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of -141C Ins/Del Polymorphism in DRD2 Gene on Clinical Symptoms and Plasma Homovanillic Acid Levels in the Treatment of Schizophrenia With Aripiprazole.
    Miura I; Kanno-Nozaki K; Hino M; Horikoshi S; Ota T; Mashiko H; Niwa S; Yabe H
    J Clin Psychopharmacol; 2015 Jun; 35(3):333-4. PubMed ID: 25871573
    [No Abstract]   [Full Text] [Related]  

  • 17. Diurnal variation of plasma cortisol and homovanillic acid in healthy subjects.
    Posener JA; Schildkraut JJ; Samson JA; Schatzberg AF
    Psychoneuroendocrinology; 1996 Jan; 21(1):33-8. PubMed ID: 8778902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma HVA, neuroleptics, and dopaminergic plasticity.
    Dávila R
    Biol Psychiatry; 1989 Jan; 25(1):1-3. PubMed ID: 2563229
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of plasma homovanillic acid over 13 months in patients with schizophrenia; relationship with the clinical response and the Wisconsin card sort test.
    Zumárraga M; González-Torres MA; Arrue A; Dávila R; Dávila W; Inchausti L; Pérez-Cabeza L; Fernández-Rivas A; Bustamante S; Basterreche N; Guimón J
    Neurochem Res; 2011 Aug; 36(8):1336-43. PubMed ID: 21475956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.